Society for Immunotherapy of Cancer | Strategic Alliance Partners

Latest from Society for Immunotherapy of Cancer

Cabozantinib Plus Nivolumab/Ipilimumab Under Exploration in Intermediate-, Poor-Risk RCC

November 14, 2020

November 14, 2020 - A novel combination comprised of the TKI cabozantinib plus the PD-1 inhibitor nivolumab and the CTLA-4 inhibitor ipilimumab is under exploration in treatment-naïve patients with intermediate or poor risk advanced or metastatic renal cell carcinoma in the phase 3 COSMIC-313 trial.

Investigational PI3K-γ Inhibitor Eganelisib Plus Nivolumab Elicits Early Efficacy in Head and Neck Cancer, Melanoma

November 13, 2020

November 13, 2020 - Treatment with the combination of eganelisib, a selective PI3K-γ inhibitor, and nivolumab demonstrated encouraging clinical activity and a favorable safety profile in patients with head and neck squamous cell carcinoma.

Urelumab Induces Additive Benefit With Vaccine/Nivolumab Combo in Pancreatic Cancer

November 13, 2020

November 13, 2020 – The addition of urelumab, an anti-CD137 agonist to the GVAX vaccine and nivolumab led to a 30% pathologic response rate and was associated with mild toxicity as neoadjuvant or adjuvant therapy in patients with resectable pancreatic ductal adenocarcinoma.

CD47 Blocker ALX148 Safe to Combine With Antibody Regimens, Chemotherapy in Gastric/GEJ and HNSCC

November 13, 2020

November 13, 2020 - ALX148 showcased favorable safety and elicited objective responses when combined with trastuzumab, pembrolizumab, and multiagent chemotherapy regimens in patients with gastric/gastroesophageal junction cancer and head and neck squamous cell carcinoma.

Cabozantinib/Pembrolizumab Trial Poised to Improve Efficacy, Safety in Advanced Melanoma

November 12, 2020

November 12, 2020 - In an effort to further improve outcomes without sacrificing tolerability, the combination of cabozantinib with pembrolizumab is being evaluated in patients with advanced melanoma in a phase 1b/2 study.

Dr. Atkins on Sequencing of Immunotherapy Combination Regimens

August 03, 2017

Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of oncology and medicine, Georgetown University School of Medicine, discusses sequencing of immunotherapy combination regimens for patients with renal cell carcinoma (RCC).

Potential Role of Immunotherapy in the Treatment of Patients With Sarcoma

June 23, 2017

Lisa H. Butterfield, PhD, professor of medicine, surgery, and immunology, director, University of Pittsburgh Immunologic Monitoring and Cellular Products Laboratory, University of Pittsburgh, president of the Society for Immunotherapy of Cancer, discusses the potential role for immunotherapy in the treatment of patients with sarcoma.

"Advancing Hope": SITC Designs Innovative Educational Experience for the Management of NSCLC

November 23, 2016

Lung cancer alone accounts for 26.5% of all cancer-related mortalities in the United States, which is more than any other malignancy. Despite increased awareness that smoking is an important risk factor for lung cancer, which has reduced the number of smokers in the U.S., nearly a quarter of a million new diagnoses are expected in 2016.

Dr. Kaufman on T-VEC in Melanoma

October 07, 2016

Howard L. Kaufman, MD, chief surgical officer, associate director for Clinical Science, surgical oncologist, Rutgers Cancer Institute of New Jersey, discusses oncolytic immunotherapy talimogene laherparepvec (T-VEC; Imlygic) for treatment of patients with melanoma, as well as the agent's side effect profile.

Society for Immunotherapy of Cancer: Leading the Way

October 04, 2016

OncLive is pleased to announce that the Society for Immunotherapy of Cancer (SITC) has joined the OncLive Strategic Alliance Partnership program, a collaborative effort to bring up-to-date clinical information to practicing oncology specialists.